ライフサイエンスコーパス: MSSA

1 MSSA IE isolates were significantly more likely to be CC

2 MSSA isolates belonged to 17 sequence type (ST) groups.

3 MSSA isolates from colonized or VAT patients exhibited s

4 MSSA recovery also increased significantly when using br

5 MSSA showed no collective inter-annual patterns of oscil

6 MSSA strains with strong blood agar hemolysis and high a

7 e bottles (identified as 10 MRSA strains, 10 MSSA strains, 12 coagulase-negative Staphylococcus strai

8 A cases were matched to 207 controls and 112 MSSA cases to 208 controls.

9 Within common MRSA clonal complexes, 3/14 MSSA and 2/21 PSSA isolates arose from the loss of resis

10 A total of 21 MSSA isolates and 37 MRSA isolates recovered from infect

11 typed in 2001 and 2002 and only 43.4% of 237 MSSA isolates typed in 2003 and 2004.

12 rmed abscess were identified: 30 MRSA and 24 MSSA.

13 Within CC8, all 38 MRSA (USA300) and all 28 MSSA isolates harbored the R variant.

14 had 3978 invasive S aureus infections (2868 MSSA and 1110 MRSA).

15 lthough they accounted for only 51.3% of 316 MSSA isolates typed in 2001 and 2002 and only 43.4% of 2

16 lates (8.0%) (MRSA, 18/173 isolates [10.4%]; MSSA, 5/114 isolates [4.4%]).

17 were examined in a diverse collection of 42 MSSA isolates.

18 % [SCCmec II], 8.3% [other MRSA], and 15.6% [MSSA]).

19 and hand carriage was found in 24.9% (20.7% MSSA and 4.1% MRSA).

20 y identified culture controls for MRSA (76), MSSA (12), and confounder organisms (36) with 100% sensi

21 A total of 93 MSSA isolates and 2 MRSA isolates were recovered from 15

22 A recurrent infection was defined as a MSSA blood culture between 45 and 365 days after the fir

23 anc results in the fewest patients achieving MSSA cure and the highest rate of recurrence (67.3%/14.8

24 te that ceftaroline is highly active against MSSA and MRSA isolated from US medical centers, independ

25 When tested against MSSA, levofloxacin resistance was higher among isolates

26 Among MSSA-bacteremic patients who did not die or get hospital

27 nt predictor for incision and drainage among MSSA strains.

28 ong MRSA of PFGE type USA300, was rare among MSSA USA300 in both time periods.

29 USA900 were the predominant PFGE types among MSSA isolates in both the 2001 to 2002 and the 2003 to 2

30 gence is apparently due to acquisition by an MSSA of the Staphylococcal Cassette Chromosome that bear

31 In total, 124 patients had an MSSA osteoarticular infection; 64 (52%) had orthopedic h

32 nd Multi-channel Singular Spectrum analysis (MSSA) methods are applied, on the shoreface, to three po

33 We detected MRSA (n = 240) and MSSA (n = 119) in 22 of 44 (50%) and 24 of 44 (55%) wast

34 Mu50, NCTC 8325, EMRSA-16 [strain 252], and MSSA-476).

35 us type IVa (13.5%), other MRSA (12.5%), and MSSA (8.9%).

36 mixed infections of CoNS and MRSA, CoNS and MSSA, or nonstaphylococci, respectively, with an overall

37 on), antibacterial activity against MRSA and MSSA and cytotoxicity against NCI-H460, MCF-7 and HeLa.

38 This study demonstrates that MRSA and MSSA can be accurately differentiated by FCM after 2 h o

39 this study was to determine whether MRSA and MSSA could be reliably differentiated by FCM.

40 We evaluated MRSA and MSSA endotracheal aspirates (ETA) for genotype and alpha

41 no significant differences between MRSA and MSSA HCAP patients in mortality (29% versus 20%, respect

42 bal SERS-based dendrogram model for MRSA and MSSA identification and differentiation to the strain le

43 incidence of HO-SAB caused by both MRSA and MSSA in Australian hospitals since 2002.

44 Infant mortality after invasive MRSA and MSSA infections is similar, but MSSA causes more infecti

45 ffer between patients who developed MRSA and MSSA infections.

46 ing method was able to discriminate MRSA and MSSA isolates according to their specific epidemiologica

47 The impact of duplicate MRSA and MSSA isolates was evaluated by using the ratio of isolat

48 ety-three percent and 29% of unique MRSA and MSSA isolates, respectively, were multidrug resistant.

49 de) were active against 24 clinical MRSA and MSSA isolates.

50 The relative proportions of MRSA and MSSA skin culture isolates were measured, along with ant

51 Samples were analyzed for MRSA and MSSA using membrane filtration.

52 eus (including clinical isolates of MRSA and MSSA) and Staphylococcus epidermidis identified one cand

53 range of S. aureus, including both MRSA and MSSA.

54 r detection of bacteremia caused by MRSA and MSSA.

55 ially passaged clinical isolates of MRSA and MSSA.

56 oresis (CZE) to distinguish between MRSA and MSSA.

57 ) methicillin-resistant S. aureus (MRSA) and MSSA SSTIs were comparable.

58 MRSA- and MSSA-infected patients were similar with regard to age,

59 Patients who were MRSA-negative and MSSA-negative bathed with CHG the night before and morni

60 nd that the patterns extracted using SSA and MSSA agree well with previous patterns identified using

61 .7% sensitivity; 904/907) were classified as MSSA by the BD Max StaphSR assay, due to negative result

62 The 23 recovered isolates were confirmed as MSSA by a variety of phenotypic methods, including the B

63 maining isolates were not MRSA and tested as MSSA by phenotypic and genotypic assays.

64 h a major community- and hospital-associated MSSA pathogen in the Dominican neighborhood of northern

65 ldren with methicillin-susceptible S aureus (MSSA) treated with vancomycin compared with 2.6% (22 of

66 hicillin-sensitive and -resistant S. aureus (MSSA and MRSA) that may influence host colonization and

67 eptible and methicillin-resistant S. aureus (MSSA and MRSA, respectively) in samples taken directly f

68 nts to be methicillin-susceptible S. aureus (MSSA) (74/84 [88.1%] versus 56/106 [52.8%], respectively

69 e against methicillin-susceptible S. aureus (MSSA) (MIC(50), 0.25 mug/mL; MIC(90), 0.25 mug/mL; 100.0

70 ents with methicillin-susceptible S. aureus (MSSA) (n = 2,367) infections had duplicate isolates.

71 RSA) (n=8), methicillin-sensitive S. aureus (MSSA) (n=7), and Escherichia coli (n=7).

72 MRSA) and methicillin-susceptible S. aureus (MSSA) among all CAP episodes.

73 (83%) had methicillin-susceptible S. aureus (MSSA) and 73 (17%) had methicillin-resistant S. aureus (

74 h MRSA or methicillin-susceptible S. aureus (MSSA) and control children infected with influenza virus

75 luated HO methicillin-susceptible S. aureus (MSSA) and HO methicillin-resistant S. aureus (MRSA) BSIs

76 iation of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) from 30

77 t against methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA).

78 iation of methicillin-susceptible S. aureus (MSSA) and MRSA directly from positive blood cultures has

79 fferentiate methicillin-sensitive S. aureus (MSSA) and MRSA using clinical isolates from China and th

80 r MRSA or methicillin-susceptible S. aureus (MSSA) and who received initially appropriate antibiotic

81 MRSA and methicillin-susceptible S. aureus (MSSA) anovaginal colonization in pregnant women, to asse

82 o carried methicillin-susceptible S. aureus (MSSA) as less prevalent flora.

83 MRSA and methicillin-susceptible S. aureus (MSSA) at U.S. wastewater treatment plants.

84 ) CFU/ml of methicillin-sensitive S. aureus (MSSA) attenuation of light transmission was less than 1.

85 (MRSA) or methicillin-susceptible S. aureus (MSSA) burden in the airways.

86 in MRSA and methicillin-sensitive S. aureus (MSSA) cases.

87 MRSA) and methicillin-susceptible S. aureus (MSSA) clinical isolates, 149 (66.2%) of 225 and 17 (56.6

88 Mu50, and methicillin-susceptible S. aureus (MSSA) controls were included.

89 -susceptible penicillin-resistant S. aureus (MSSA) did not change.

90 only for methicillin-susceptible S. aureus (MSSA) from an enrichment broth.

91 mens grew methicillin-susceptible S. aureus (MSSA) from broth enrichment culture, of which two demons

92 MRSA) and methicillin-susceptible S. aureus (MSSA) in cases of clinical bacteremia may promote approp

93 he place of methicillin-sensitive S. aureus (MSSA) in many communities.

94 ts of ST8 methicillin-susceptible S. aureus (MSSA) isolated in Africa represent a symplesiomorphic gr

95 MRSA) and methicillin-susceptible S. aureus (MSSA) isolates and reference strains were compared.

96 ential that methicillin-sensitive S. aureus (MSSA) isolates have for acquiring SCCmec, the nucleotide

97 h African methicillin-susceptible S. aureus (MSSA) isolates were more likely to carry certain virulen

98 MRSA) and methicillin-susceptible S. aureus (MSSA) isolates yielded side-scatter (SSC) and fluorescen

99 ng the 39 methicillin-susceptible S. aureus (MSSA) isolates, 29 harbored the R variant.

100 ) and 900 methicillin-susceptible S. aureus (MSSA) isolates.

101 MRSA and methicillin-susceptible S. aureus (MSSA) on TSA II was 12.4% (64/515) and 9.7% (50/515), re

102 MRSA and methicillin-susceptible S. aureus (MSSA) per calendar year, stratified into CO and HO infec

103 ents with methicillin-susceptible S. aureus (MSSA) SSTIs and those with MRSA SSTIs.

104 -positive methicillin-susceptible S. aureus (MSSA) strains has not been investigated.

105 MRSA) and methicillin-susceptible S. aureus (MSSA) strains with different levels of PVL production.

106 alence of methicillin-susceptible S. aureus (MSSA) was 84%, while MRSA herd prevalence was 4%.

107 wounds and methicillin-sensitive S. aureus (MSSA) was recovered from 24.

108 (MRSA) or methicillin-susceptible S. aureus (MSSA) were asked to apply mupirocin intranasally twice d

109 SA versus methicillin-susceptible S. aureus (MSSA) were identified.

110 MRSA) and methicillin-susceptible S. aureus (MSSA) with sensitivities of 100% each and specificities

111 es, 16 were methicillin-sensitive S. aureus (MSSA), 207 were methicillin-resistant S. aureus (MRSA) a

112 of MRSA, methicillin-susceptible S. aureus (MSSA), and confounders were included as controls.

113 pposed to methicillin-susceptible S. aureus (MSSA), are more likely to have abused alcohol in the pas

114 iology of methicillin-susceptible S. aureus (MSSA), despite its continued clinical importance.

115 s (MRSA), methicillin-susceptible S. aureus (MSSA), or mixed infections of CoNS and MRSA, CoNS and MS

116 olates as methicillin-susceptible S. aureus (MSSA), while one MSSA isolate tested negative for S. aur

117 caused by methicillin-susceptible S. aureus (MSSA).

118 ized with methicillin-susceptible S. aureus (MSSA).

119 .7%) were methicillin-susceptible S. aureus (MSSA).

120 isease as methicillin-susceptible S. aureus (MSSA).

121 d 36 were methicillin-susceptible S. aureus (MSSA).

122 thicillin-susceptible Staphylococcus aureus (MSSA) (14), methicillin-resistant Staphylococcus epiderm

123 thicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) isolate

124 Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a morbid infection.

125 thicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections.

126 thicillin-susceptible Staphylococcus aureus (MSSA) CC398 isolates of known human origin.

127 thicillin-susceptible Staphylococcus aureus (MSSA) clone sequence type (ST) 398 has increasingly been

128 thicillin-susceptible Staphylococcus aureus (MSSA) infection.

129 thicillin-susceptible Staphylococcus aureus (MSSA) infections, beta-lactams are recommended for defin

130 methicillin-sensitive Staphylococcus aureus (MSSA) infections.

131 thicillin-susceptible Staphylococcus aureus (MSSA) isolates from infective endocarditis (IE) and soft

132 thicillin-susceptible Staphylococcus aureus (MSSA) isolates lacking mecA yet testing positive on the

133 thicillin-susceptible Staphylococcus aureus (MSSA) strains and comprised six distinct clones, which c

134 methicillin-sensitive Staphylococcus aureus (MSSA) strains.

135 thicillin-susceptible Staphylococcus aureus (MSSA), and recent studies have suggested similar clinica

136 thicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA

137 thicillin-susceptible Staphylococcus aureus (MSSA), only one dimer was more potent against methicilli

138 meticillin)-sensitive Staphylococcus aureus (MSSA).

139 tetracyclin-resistant Staphylococcus aureus (MSSA, MRSA, and TRSA, respectively) and vancomycin-resis

140 1997 (75 methicillin-susceptible S. aureus [MSSA] and 30 MRSA isolates) in order to investigate for

141 ] and 114 methicillin-susceptible S. aureus [MSSA] isolates) from patients from 127 centers in 34 cou

142 ] and 254 methicillin-susceptible S. aureus [MSSA]) were genotyped by spa typing and multilocus seque

143 and 1 had methicillin-susceptible S. aureus [MSSA]), 8 (2.9%) had zone sizes that measured 19 mm (6 h

144 ed MRSA (or methicillin-sensitive S. aureus [MSSA]).

145 thicillin-susceptible Staphylococcus aureus [MSSA] and 6.3% methicillin-resistant S. aureus [MRSA]),

146 e isolates (methicillin-sensitive S. aureus: MSSA).

147 ing difference in the roles of arlRS between MSSA and MRSA strains is not due to the methicillin resi

148 re no overall prognostic differences between MSSA- and MRSA-PJI, but there was a higher incidence of

149 o 13 duplicates/year) did not switch between MSSA and MRSA but retained the original S. aureus strain

150 Most USA200 isolates (both MSSA and MRSA) carried the gene for toxic shock syndrome

151 l successfully allowed the detection of both MSSA and MRSA contaminating important high-touch surface

152 ive MRSA and MSSA infections is similar, but MSSA causes more infections and more deaths in infants t

153 quickly differentiating bacteremia caused by MSSA and MRSA from that caused by other gram-positive co

154 AP patients (n = 15) were mainly infected by MSSA strains (87%), whereas colonized individuals (n = 1

155 ected with CA-MRSA (n = 102 patients) and CA-MSSA (n = 102 patients) had median ages of 46 and 53 yea

156 of the patients infected with CA-MRSA and CA-MSSA, respectively, were hospitalized (P < 0.001).

157 y were 12 and 10 days in the CA-MRSA- and CA-MSSA-infected patients, respectively; 48 and 56% of the

158 cillin-susceptible Staphylococcus aureus (CA-MSSA) infections were prospectively identified.

159 ith a more adverse impact on outcome than CA-MSSA infections.

160 Among the CA-MSSA isolates there were 33 PFGE groups, with isolates o

161 A-MRSA infections and 3% of patients with CA-MSSA infections had household contacts with similar infe

162 clinical MSSA (n = 103), and nasal carriage MSSA (n = 113), collected over a 19-year period in two M

163 marily to USA300 MRSA, we found that all CC8 MSSA isolates also contained the R variant, suggesting t

164 defined clinical CA-MRSA (n = 77), clinical MSSA (n = 103), and nasal carriage MSSA (n = 113), colle

165 Genotypically, nasal carriage and clinical MSSA isolates were much more diverse than was the CA-MRS

166 compared to the nasal carriage and clinical MSSA strains probably contributed to their enhanced viru

167 eus biofilms formed by a variety of clinical MSSA and MRSA strains and created culture-negative impla

168 genes than did the carriage and the clinical MSSA group (range, 0% to 58%).

169 rienced a stable incidence of CO-MRSA and CO-MSSA bacteremia.

170 patient-days in 2011 [P = .005]), whereas CO-MSSA rates remained stable.

171 ates had higher SSC and FI readings than did MSSA isolates after 2 h of incubation.

172 Eight MSSA isolates (99.1% sensitivity; 892/900) were assigned

173 , 99.1% were correctly categorized as either MSSA or MRSA.

174 e arisen repeatedly from successful epidemic MSSA strains, and isolates with decreased susceptibility

175 SCCmec types (16.7 to 20.7%); each exceeded MSSA (6.7%; P=0.05).

176 days before and up to 4 days after the first MSSA blood culture was collected.

177 ture between 45 and 365 days after the first MSSA blood culture.

178 707] for MRSA versus $104,121 [$91,314]) for MSSA [P = 0.712]).

179 ibiotic therapy (86% for MRSA versus 91% for MSSA; P = 0.783).

180 e values of the BD GeneOhm StaphSR assay for MSSA detection were 98.9, 96.7, 93.6, and 99.5%, respect

181 eated with either nafcillin or cefazolin for MSSA infection in the outpatient parenteral antimicrobia

182 to 2010 who had positive blood cultures for MSSA.

183 pleted to determine whether risk factors for MSSA and MRSA breast abscess differ.

184 Oxacillin was ineffective for MSSA colonization in approximately 30% of the patients,

185 body site; no differences were observed for MSSA.

186 ons compared with nafcillin or oxacillin for MSSA infections complicated by bacteremia.

187 mparison of ceftriaxone versus oxacillin for MSSA osteoarticular infections, there was no difference

188 ded if they had a blood culture positive for MSSA and received definitive therapy with cefazolin, naf

189 was 1.90 isolates/patient, and the ratio for MSSA was 1.35.

190 was higher for MRSA (15%; 11 of 73) than for MSSA strains (5.2%; 19 of 363) (chi(2) = 9.2; P = 0.01).

191 , exposure of the biosensor to extracts from MSSA-infected mice resulted in 5.6% or less attenuation

192 d electrolyte, a CZE separation of MRSA from MSSA may be completed within 12 min.

193 Few risk factors differentiated MRSA from MSSA SSTIs, and detainee patients with MRSA SSTIs are at

194 of 0.0445 reliably differentiated MRSA from MSSA.

195 y MRSA and to distinguish these strains from MSSA and BORSA, by specifically detecting PBP2a.

196 .6%) had zone sizes of >/=21 mm (all 137 had MSSA).

197 es that measured 19 mm (6 had MRSA and 2 had MSSA), 8 (2.9%) had zone sizes that measured 20 mm (6 ha

198 es that measured 20 mm (6 had MRSA and 2 had MSSA), and 137 (49.6%) had zone sizes of >/=21 mm (all 1

199 SA (from 0.77 to 0.18 per 10 000 PDs) and HO-MSSA (from 1.71 to 0.64 per 10 000 PDs) bacteremia were

200 most of the sites, HO-MRSA decreased and HO-MSSA rates were stable.

201 ifampin may have contributed to homogenizing MSSA and MRSA prognoses, although the specific rifampin

202 However, MSSA and MRSA strains that produced high levels of PVL c

203 The distinct human MSSA CC398 spa type, t571, was not present among our MRS

204 imilar use of rifampin-based combinations in MSSA- and MRSA-PJI.

205 that ArlRS impacts autolysis differently in MSSA and MRSA strains.

206 to prevent S aureus infection should include MSSA in addition to MRSA.

207 ospital discharge was similar after invasive MSSA and MRSA infections (risk ratio, 1.19; 95% CI, 0.96

208 oportions of infants who died after invasive MSSA and MRSA infections were similar at 237 of 2474 (9.

209 n were similar between infants with invasive MSSA infection and infants with invasive MRSA infection.

210 e mortality data, more infants with invasive MSSA infections (n = 237) died before hospital discharge

211 First-line MSSA therapies (nafcillin, oxacillin, cefazolin) are gen

212 Most MSSA isolates remained susceptible to all antimicrobial

213 In contrast to those of MRSA, MSSA infectious isolates show wide genetic diversity wit

214 A chart review of 31 patients with MRSA, MSSA, or VRE demonstrated that the Nanosphere BC-GP assa

215 t of the data revealed that the KeyPath MRSA/MSSA blood culture test delivered results a median of 30

216 mpared to standard methods, the KeyPath MRSA/MSSA blood culture test demonstrated a sensitivity, spec

217 e performance of the MicroPhage KeyPath MRSA/MSSA blood culture test was compared to conventional ide

218 Detection of MRSA/MSSA in blood cultures could be reported 10 to 24 h earl

219 esembled MRSA CC398 as found in pigs and not MSSA CC398 as found in humans.

220 ignificantly associated with HO-MRSA but not MSSA BSIs.

221 (95% confidence interval, 2.1% to 32.6%) of MSSA SSTI patients (P = 0.004).

222 Overall, 7.1% (64/900) of MSSA isolates showed results compatible with a mecA drop

223 Colonization of MSSA and MRSA, risk factors for colonization, antimicrob

224 2.34), while there was a higher incidence of MSSA-PJI treatment failure after therapy.

225 ients, 64 (29.8%) had at least 1 incident of MSSA reversion, and 55 (25.6%) reverted to MSSA infectio

226 2 were defined to encompass the majority of MSSA and MRSA signal events, respectively.

227 ition, the attB sequences of the majority of MSSA isolates in this collection differ from the attB se

228 e autolytic phenotype in the arlRS mutant of MSSA strain Newman could be rescued by a mutation in eit

229 We compared patient outcomes of MSSA osteoarticular infections treated with ceftriaxone

230 The isoelectric points of MSSA and MRSA were found to be the same for both groups

231 E) analysis revealed a diverse population of MSSA strains.

232 The prevalences of MSSA, MRSA, and GBS colonization were 11.8%, 0.6% and 23

233 The overall relative proportion of MSSA was 64.3%.

234 was 33.3%, while the relative proportion of MSSA was 66.7%.

235 el of toxin produced and (2) many strains of MSSA that cause soft-tissue infections produce higher le

236 In this case-control study of MSSA infections, we identified ST398 MSSA as both a majo

237 omycin for empiric and definitive therapy of MSSA bloodstream infections among patients admitted to 1

238 n innate immunomodulator in the treatment of MSSA and MRSA surgical wound infection through enhanceme

239 (63.5%) were of MRSA and 43 (11.4%) were of MSSA; 84.8% of S. aureus isolates were MRSA.

240 llin-susceptible S. aureus (MSSA), while one MSSA isolate tested negative for S. aureus.

241 Additionally, infection with MRSA as opposed MSSA doubled the probability of needing continued ICU ca

242 characteristics and mortality after MRSA or MSSA infection.

243 Infants with invasive MRSA or MSSA infections had similar gestational ages and birth w

244 None of the MRSA or MSSA isolates contained arcA or opp3.

245 red when decisions for outpatient parenteral MSSA treatment are made.

246 One phenotypic MSSA isolate contained an intact SCCmec.

247 fits of distinguishing between mecA-positive MSSA and MRSA in clinical reports should be evaluated.

248 o methicillin resistance among mecA-positive MSSA within a patient during antibiotic therapy.

249 Notably, the prevalent MSSA strains (spa t002 and spa t008) are analogous to th

250 icillin-sensitive Staphylococcus aureus (PVL-MSSA) clinical isolates.

251 etection of PVL phages and haplotypes in PVL-MSSA identical to those previously found in PVL-MRSA iso

252 Characterization of PVL-MSSA isolates by multilocus sequence typing (MLST) and s

253 nt SA (MRSA) and methicillin-susceptible SA (MSSA) infections differ is unknown.

254 he incidence rate for methicillin-sensitive (MSSA) was 2.1 per 100 outpatient-years, and the incidenc

255 tudy of MSSA infections, we identified ST398 MSSA as both a major community- and hospital-associated

256 ed clones (ST47-MSSA, ST30-MRSA-IV[2B], ST45-MSSA, and ST22-MRSA-IV[2B]) compared with none and 1 of

257 nd in 4 of the 5 highest-ranked clones (ST47-MSSA, ST30-MRSA-IV[2B], ST45-MSSA, and ST22-MRSA-IV[2B])

258 nstrated the ability to revert to subsequent MSSA SSTIs with a significant frequency.

259 reference laboratories collected successive MSSA isolates from patients with invasive or superficial

260 resistant (MRSA) or methicillin-susceptible (MSSA) HCAP, based on initial S. aureus isolates.

261 ostchallenge with a methicillin-susceptible (MSSA) or a methicillin-resistant (MRSA) strain of S. aur

262 esistant (MRSA) and methicillin-susceptible (MSSA) S. aureus strains.

263 esistant (MRSA) and methicillin-susceptible (MSSA) S. aureus strains.

264 Every tenth MSSA isolate and all MRSA isolates were typed by pulsed-

265 MRSA isolates were more often clonal than MSSA isolates by PFGE.

266 distinct repertoire of virulence genes than MSSA STI isolates from the same region.

267 States, MRSA isolates were more likely than MSSA isolates to carry genes for sdrC (P = 0.03), map/ea

268 n; 17 (7.5%) of the MRSA and 2 (6.6%) of the MSSA isolates grew on BHI screening plates containing 4

269 In 4 of the 6 patients, the MSSA was unrelated to prevalent MRSA, as determined by p

270 egulated in the arlRS mutant of MW2 than the MSSA strain Newman.

271 However, six of these MSSA isolates had the mecA gene confirmed by PCR and seq

272 ociated with an increased risk of SSI due to MSSA when compared with prophylaxis with a beta-lactam a

273 f MSSA reversion, and 55 (25.6%) reverted to MSSA infections for the remainder of the study.

274 positive in subsequent SSTIs or reverted to MSSA-positive infections.

275 t the gene level, CA-MRSA is more similar to MSSA than HA-MRSA: its emergence is apparently due to ac

276 lusion, vancomycin is commonly used to treat MSSA bacteremia in outpatients receiving chronic dialysi

277 Twelve MSSA isolates tested positive for MRSA by the BD-MRSA PC

278 In all ICU types, MSSA central line-associated BSI incidence declined from

279 S. aureus HCAP, irrespective of MRSA versus MSSA status, is associated with significant mortality an

280 the original S. aureus strain whether it was MSSA or MRSA.

281 Model outcomes included 12-week MSSA cure, recurrence, and death; allergic reactions inc

282 0: 34 of these strains were MRSA and 12 were MSSA.

283 e colonizing isolates were MRSA, and 14 were MSSA, and the majority of the colonizing isolates belong

284 112 total samples, 27 (24%) and 5 (4%) were MSSA- and MRSA-positive, respectively.

285 The most frequent pathogens were MSSA, methicillin-resistant Staphylococcus aureus, and P

286 ecame more sensitive to ciprofloxacin, while MSSA became more resistant to ciprofloxacin, clindamycin

287 ecame more sensitive to ciprofloxacin, while MSSA demonstrated increased antibiotic resistance to cip

288 uding 15 (0.7%) with MRSA and 22 (1.0%) with MSSA; 115 (5.1%) had Streptococcus pneumoniae Vancomycin

289 1.01-3.18) as significantly associated with MSSA acquisition.

290 This contrasts with MSSA strains, including Newman, SH1000, RN6390, and 8325

291 dex blood culture, 56.1% of outpatients with MSSA bacteremia were receiving vancomycin, and 16.7% of

292 ng vancomycin, and 16.7% of outpatients with MSSA were receiving cefazolin.

293 Patients with MSSA bacteremia and a reported PCN allergy should have t

294 l evaluation and treatment for patients with MSSA bacteremia and reported PCN allergy.

295 For patients with MSSA bloodstream infections, beta-lactams are superior t

296 SA coinfection (9 died) and 22 patients with MSSA coinfection (all survived).

297 s nafcillin or oxacillin among patients with MSSA infections complicated by bacteremia.

298 retrospective cohort study of patients with MSSA osteoarticular infections at a tertiary care hospit

299 Characteristics of persons with MSSA and MRSA seem to differ.

300 pared patients with MRSA VAP to persons with MSSA VAP.

301 The adjusted odds ratio (OR) for an SSI with MSSA was 2.79, where vancomycin prophylaxis was administ